Biopharma investors set plans for expedited ROI by developing products, not companies
This article was originally published in Scrip
If the biotechnology industry initially embraced a credo of "The Little Engine that Could" – the story of a little railroad engine with 'can-do' attitude - a more relevant description of the last 10 years may be "Little Big Pharma," according to a recent meeting of a group of investors and executives.
You may also be interested in...
Biotech companies and their backers are looking at 2012 with guarded optimism. Delegates and panellists at the recent BIO Investor Forum in San Francisco believe that the recent restructuring of companies is restoring investor confidence in the sector, with an increase interest in taking discovery platform businesses public. Moreover, participants at the meeting were predicting that biotech companies have nothing to fear from the FDA or the US presidential elections.